Affimed N.V.

General information

Affimed N.V.
Gottlieb-Daimler-Straße 2
68165 Mannheim, Baden-Württemberg
Germany

Contact person: Shawn M. Leland, Chief Executive Officer
Company main phone: +49 (621) 560030
Company main fax: +49 (621) 56003649
Website: https://www.affimed.com

Year founded:	2000
Source of foundation:	Spin-off from public institution / NPO
Name of foundation source:	German Cancer Research Centre (DKFZ)
No. of employees:	Worldwide: 76

Corporate description / mission:
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells.

State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2014

Categorization

Sector:

Biotechnology - Therapeutics and Diagnostics

Subsector:

Antibodies
Cell therapy
Immunotherapy

Primary therapeutic areas:

Neoplasms / cancer / oncology

Business model:

Out-licensing
R&D

Customer segments:

Other
Large biotech & big pharma
Small biotech

Distribution:

Indirect (independent dealer)

Summary Products / Services / Technologies

Number of Biotech Products

Pre-clinical:	3
Phase I:	2
Phase II:	2

Description of products:
AFM13
AFM24
AFM28
AFM32, etc.

Technology used:
ROCK® Platform

Financing details

Market cap. / valuation:

USD 2.98M

Collaborations & Clients

Partnering strategy / collaborations:
Genentech
Artiva
Roche
Merck, etc.